Yakup Ergün, Medical Oncologist at Bower Hospital, shared on X:
“Some breakthroughs deserve to be celebrated.
Daraxonrasib in pancreatic cancer is one of them.
After decades of very limited progress in this disease, and finally seeing these results by targeting RAS-long considered ‘undruggable’-I’ve read so many BUTs on social media:
- What do we do when resistance emerges?
- Will it work in earlier-stage disease?
- Can combinations improve outcomes further?
- What about long-term outcomes?
These are all important scientific questions. In time, they will naturally emerge and be addressed.
That’s how science moves forward.
But expecting a breakthrough therapy to answer every question about a disease from day one is not a reasonable way to judge progress.
Sometimes, we should simply acknowledge the achievement first.
Because many of the questions we are asking today could not even have been asked yesterday-we didn’t have a therapy that made them relevant.
So, to those with another ‘BUT’: please share your data-or stay quiet for a while. Most of us haven’t even seen the drug’s box yet.”
You can also read: Daraxonrasib for Pancreatic Cancer: What’s Next?
